MMP Family Antibody Selection

The matrix metalloproteinase (MMP) family comprises 23 human members, spanning secreted collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9), stromelysins (MMP-3, -10, -11), matrilysins (MMP-7, -26), membrane-type MMPs (MT1-MMP through MT6-MMP; MMP-14, -15, -16, -17, -24, -25), and a heterogeneous set of orphan MMPs (MMP-12, -19, -20, -21, -23, -27, -28). Every one of them shares the same core architecture: a signal peptide, a propeptide containing the "cysteine switch" that keeps the enzyme latent, a zinc-dependent catalytic domain with the HEXXHXXGXXH motif, and (for most members) a hemopexin-like C-terminal domain that mediates substrate specificity and TIMP binding. This shared architecture is both a research asset and a pitfall — it allows generalisable antibody design, but it also creates a real risk of paralogue cross-detection.

Choosing an MMP antibody without accounting for these features is the most common source of published MMP data that fails to replicate. This guide walks through the selection decisions you have to make, and how Triple Point's full MMP-1 through MMP-28 catalogue maps to them.

The MMP domain architecture and what each domain tells you

Additional domains distinguish specific subgroups: gelatinases (MMP-2, MMP-9) carry three fibronectin type II repeats inserted within the catalytic domain that enable collagen binding; membrane-type MMPs have a C-terminal transmembrane helix and cytoplasmic tail (or a GPI anchor for MT4/MT6-MMP); MMP-23 uniquely has a cysteine array and immunoglobulin-like domain.

Latent zymogen vs active enzyme — a critical distinction for MMP detection

All MMPs are secreted as latent proenzymes. Activation requires cleavage of the propeptide, which for most MMPs happens extracellularly via other proteases (plasmin, trypsin, and other MMPs) or intracellularly via furin (for MMPs with the RXKR/RXRXKR furin recognition motif: MMP-11, MMP-14, MMP-15, MMP-16, MMP-17, MMP-21, MMP-23, MMP-24, MMP-25, MMP-28). The MW difference between latent and active is approximately 10 kDa (the mass of the propeptide).

A Western blot showing both latent and active forms as separate bands is not a contamination artefact — it is the normal steady-state population of most tissues. Reporting an MMP as "active in the sample" requires either:

1. A propeptide-directed antibody demonstrating the presence of the active-MW band without a corresponding latent-MW band, or
2. A catalytic-domain antibody demonstrating the size shift with an activator control, or
3. A gelatin zymography confirmation of enzymatic activity at the active MW (applicable to MMP-2, MMP-9, and by extension other gelatin-degrading MMPs).

Paralogue cross-reactivity — the specific pitfalls

Sequence identity across MMP catalytic domains ranges from 35% to 85% depending on the pair. The highest-risk pairs for cross-reactivity are:

Triple Point's approach to paralogue discrimination is to raise separate polyclonals against peptides from divergent surface loops of the catalytic domain and from the hinge and hemopexin domains, then measure cross-reactivity against the paralogue's homologous peptide on the CoA. Where cross-reactivity is measurable, it is reported.

The Triple Point MMP catalogue — navigation

The catalogue provides polyclonal antibodies to every human MMP, plus recombinant control proteins and Superpooled kits for the highest-priority members. Specific SKUs of note:

Choosing the right domain antibody for your question

"Is this MMP expressed?"

Use a catalytic-domain-directed antibody (RP1 series or equivalent) as first-line detection. Catalytic-domain signal covers both proenzyme and active forms, giving the highest sensitivity for total-MMP quantitation. Confirm the observed MW matches the CoA-reported expected size for both latent and active forms.

"Is this MMP being activated?"

Combine a propeptide-directed antibody (detects proenzyme only) with a catalytic-domain antibody (detects both). A loss of propeptide signal with retention of a lower-MW catalytic-domain band demonstrates activation. Alternative approach for MMP-2 and MMP-9: gelatin zymography, which shows only the active (or trypsin-activatable) enzyme by substrate degradation.

"Is this MMP membrane-anchored or shed?"

For MT-MMPs (MMP-14, -15, -16, -17, -24, -25), combine a catalytic-domain antibody with a C-terminal / transmembrane-directed antibody. Membrane fractions should show both. Shed forms in conditioned media should show only catalytic-domain signal at a slightly lower MW.

"Which MMP is doing this cleavage?"

This question can only be resolved with paralogue-specific antibodies plus loss-of-function controls (siRNA, inhibitor). Antibody detection alone shows expression, not causation. Pair Western blot with a specific inhibitor (e.g., a TIMP-3-selective inhibitor for MT-MMPs, or a barbiturate-based collagenase inhibitor).

Cross-reactivity control blots — how to design them

The single most useful blot for any MMP experiment is a paralogue-panel control run once at the start of the project:

1. Load recombinant catalytic domains of the two or three most closely-related paralogues in adjacent lanes (10 ng each).
2. Probe with your MMP-specific antibody at working dilution.
3. Signal should be strong at the matched paralogue and undetectable or minimal at the mismatched paralogues.
4. Quantify the residual mismatched signal as a percentage. Document it.

Once this control is in the notebook for your specific antibody + specific detection system + specific exposure, you can interpret subsequent tissue and cell lysate blots with confidence.

Cross-species reactivity

MMP orthologue sequences are highly conserved between human, mouse, and rat — catalytic domains are typically 85-95% identical. Antibodies raised against a conserved peptide will cross-detect orthologues; antibodies raised against a species-divergent region will not. Triple Point CoAs report which species have been validated for each SKU. Where dedicated murine-specific antibodies exist (RP1MMP12M, RP1MMP24M), they are noted with an M suffix.

Common failure modes

Confusing pro-MMP with degradation products

Latent proenzyme is 10 kDa larger than the active enzyme, not smaller. Bands smaller than the expected active MW are degradation, not activation. If you see a ladder of decreasing-MW bands, your lysate has been degrading during preparation — add fresh protease inhibitors and repeat.

Detecting the "TIMP-bound" MMP as a smear

MMPs form stable complexes with TIMP inhibitors that survive SDS. If you see a high-MW smear above the expected proenzyme band, it may be an MMP-TIMP complex. Boil the sample longer (10 minutes at 95°C in reducing sample buffer) to dissociate.

Assuming zymography and Western give the same answer

Gelatin zymography detects enzymatic activity, not protein presence. A sample can have detectable MMP-9 protein by Western and no active MMP-9 by zymography, or vice versa if the enzyme is TIMP-bound. The two techniques answer different questions.

Related

• Full MMP antibody catalog
• MMP-9 vs MMP-2 antibody selection
• MMP-1 vs MMP-13 antibody selection
• TIMP-1 vs TIMP-2 antibody selection
• Western blot protocol for metalloproteinases
• Zymogens and proenzymes overview
• The Superpooled (SPA) method
• Detecting antibody cross-reactivity